Ulmer & Berne’s intellectual property (IP) and business attorneys bring a deep and broad expertise that benefits our biomed/biotechnology clients. Our attorneys counsel a wide range of clients, from scientists and entrepreneurs to companies of all sizes, at every phase of their growth cycle, including: formation and financing of early-stage ventures; technology transfers; structuring and negotiating licenses and other technology transactions, research and development collaborations and other technology collaborations; joint ventures; planning and developing intellectual property portfolios; structuring securities offerings; protecting and defending intellectual property rights; and developing and financing new research.
We understand that protecting the ideas and inventions of our biomed/biotechnology clients is critically important at every stage of development. Ulmer & Berne attorneys counsel life sciences companies during the inventive and patenting processes to strengthen the validity and scope of their patents, procure domestic and international patent rights, develop IP strategies and manage their IP portfolios. If litigation becomes necessary, our highly skilled IP litigators defend our clients’ IP rights nationwide and before the U.S. Patent and Trademark Office.
Our attorneys understand the issues that face our biomed/biotechnology clients and they work closely in order to anticipate and address the challenges these clients face at every stage of their growth and development. As a result, Ulmer & Berne delivers timely and creative solutions to client challenges in an efficient and cost-effective manner.
Press Release Ulmer & Berne LLP is pleased to announce the promotions of five of its attorneys to partner. They include Daniel Gottesman, Richard Hamilton, Jr., Jesse Lipcius, Brad Sobolewski, and Ulmer’s General Counsel, Kenneth Zirm. In addition, Ulmer also elevated associate Evelyn Holmer to counsel. Lipcius is based in...
January 05, 2017